Abstract |
Hexamethylenebis[ acetamide] ( HMBA) is an agent in clinical trial that induces differentiation of certain types of tumor cells to nonmalignant phenotypes. In an attempt to discover a more potent compound, a number of bis-functionalized amides, imides, and hydrazine derivatives of HMBA were prepared and evaluated in vitro with the HL-60 human promyelocytic leukemia cell line. Among the compounds evaluated, the 5,5-dimethylhydantoin derivative is almost 10 times more potent than HMBA in inducing differentiation. The bis- imide, diacetyl- HMBA, is both more potent and effective than its parent compound. Six of the 16 compounds evaluated cause at least 20% differentiation. An inverse relationship between the degree of differentiation and the percentage of viable cells is described for HMBA and its analogues.
|
Authors | A Haces, T R Breitman, J S Driscoll |
Journal | Journal of medicinal chemistry
(J Med Chem)
Vol. 30
Issue 2
Pg. 405-9
(Feb 1987)
ISSN: 0022-2623 [Print] United States |
PMID | 3806621
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
- Acetamides
- Indicators and Reagents
- hexamethylene bisacetamide
|
Topics |
- Acetamides
(chemical synthesis, pharmacology)
- Cell Differentiation
(drug effects)
- Cell Line
- Humans
- Indicators and Reagents
- Magnetic Resonance Spectroscopy
- Mass Spectrometry
- Structure-Activity Relationship
|